ATE417605T1 - Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität - Google Patents
Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizitätInfo
- Publication number
- ATE417605T1 ATE417605T1 AT03762927T AT03762927T ATE417605T1 AT E417605 T1 ATE417605 T1 AT E417605T1 AT 03762927 T AT03762927 T AT 03762927T AT 03762927 T AT03762927 T AT 03762927T AT E417605 T1 ATE417605 T1 AT E417605T1
- Authority
- AT
- Austria
- Prior art keywords
- cross
- beta structure
- modulating
- formation
- methods
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 230000001988 toxicity Effects 0.000 title 1
- 231100000419 toxicity Toxicity 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
- G01N2333/9726—Tissue plasminogen activator
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02077797A EP1380290A1 (de) | 2002-07-09 | 2002-07-09 | Cross-Beta-Strukturweg und seine therapeutische Relevanz |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE417605T1 true ATE417605T1 (de) | 2009-01-15 |
Family
ID=29724525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03762927T ATE417605T1 (de) | 2002-07-09 | 2003-07-08 | Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität |
Country Status (13)
Country | Link |
---|---|
US (3) | US20060045853A1 (de) |
EP (5) | EP1380290A1 (de) |
JP (1) | JP2005537254A (de) |
AT (1) | ATE417605T1 (de) |
AU (2) | AU2003251233B2 (de) |
CA (1) | CA2492010A1 (de) |
DE (1) | DE60325381D1 (de) |
DK (1) | DK1536778T3 (de) |
ES (1) | ES2319982T3 (de) |
NZ (2) | NZ537495A (de) |
PT (1) | PT1536778E (de) |
WO (1) | WO2004004698A2 (de) |
ZA (1) | ZA200500062B (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1820806A1 (de) * | 2006-02-16 | 2007-08-22 | Crossbeta Biosciences B.V. | Affinitätsbereiche |
EP1380290A1 (de) * | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-Beta-Strukturweg und seine therapeutische Relevanz |
US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
EP1704867A1 (de) * | 2005-03-18 | 2006-09-27 | Crossbeta Biosciences B.V. | Cross-Beta Strukturen auf Mikrobenorganismen |
US20090202980A1 (en) * | 2005-03-21 | 2009-08-13 | Crossbeta Biosciences B.V. | Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation |
US20080249606A1 (en) * | 2005-07-13 | 2008-10-09 | Martijn Frans Ben Gerard Gebbink | Methods for Determining the Effect of a Treatment on the Cross-Beta Structure Content of a Protein; Selection of Treatments and Uses Thereof |
US20070015133A1 (en) * | 2005-07-13 | 2007-01-18 | Umc Utrecht Holding B.V. | Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein |
ATE554394T1 (de) | 2005-07-13 | 2012-05-15 | Crossbeta Biosciences Bv | Cross-beta-struktur-bindende verbindungen |
EP1906995A2 (de) * | 2005-07-13 | 2008-04-09 | Crossbeta Biosciences B.V. | Adjuvation durch kreuzstruktur |
US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
WO2007108675A1 (en) * | 2006-03-17 | 2007-09-27 | Crossbeta Biosciences B.V. | Methods of binding of cross-beta structures by chaperones |
GB0710976D0 (en) | 2007-06-07 | 2007-07-18 | Bioalvo | Am Screening method |
EP2058001A1 (de) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Steigerung der Immunogenizität von Antigenen |
EP2058000A1 (de) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung |
WO2010062377A2 (en) * | 2008-10-31 | 2010-06-03 | Yale University | Methods and compositions for the detection and treatment of preeclampsia |
JP5432923B2 (ja) | 2008-12-22 | 2014-03-05 | 学校法人藤田学園 | Aβ除去材、Aβ除去器及びAβ除去システム |
EP2322163A1 (de) * | 2009-11-03 | 2011-05-18 | Pharnext | Neue therapeutische Ansätze zur Behandlung von Alzheimer-Krankheit |
US10112000B2 (en) | 2010-07-08 | 2018-10-30 | Asahi Kasei Medical Co., Ltd. | Method for reducing amyloid beta concentration in blood |
DE102011003944A1 (de) | 2011-02-10 | 2012-08-16 | Oxprotect Gmbh | Detektion und Entfernung von missgefalteten Proteinen/Peptiden |
US20130122076A1 (en) * | 2011-11-11 | 2013-05-16 | Mathew Gelfand | Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease |
TW202019398A (zh) * | 2018-06-28 | 2020-06-01 | 張翔毓 | 用於治療或預防構形疾病之方法及藥物篩選方法 |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60103964A (ja) * | 1983-11-10 | 1985-06-08 | ユニチカ株式会社 | 抗血栓性材料 |
US5733524A (en) | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5700447A (en) | 1992-05-21 | 1997-12-23 | The Picowder Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5869534A (en) | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
US5801200A (en) | 1984-03-19 | 1998-09-01 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
US5733933A (en) | 1984-03-19 | 1998-03-31 | The Picower Institute For Medical Research | Methods and materials for the diagnosis and treatment of conditions such as stroke |
EP0234051B1 (de) * | 1986-02-17 | 1991-12-11 | Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis | Gewebeplasminogen-Aktivator-Mutant, dafür kodierende rekombinante genetische Information und Verfahren zur Herstellung dieser Mutanten, deren Verwendung und pharmazeutische Zusammensetzungen |
EP0319144A1 (de) | 1987-11-06 | 1989-06-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Sorbentmittel für beta-2-Mikroglobulin |
US5216127A (en) | 1987-11-20 | 1993-06-01 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Adsorbent for serum amyloid protein |
JPH01171638A (ja) * | 1987-12-25 | 1989-07-06 | Kanegafuchi Chem Ind Co Ltd | 血清アミロイドa蛋白用吸着体 |
DE3880647T2 (de) | 1987-11-20 | 1993-11-18 | Kanegafuchi Chemical Ind | Sorbentmittel für Serum-Amyloid-Proteine. |
US5151082A (en) * | 1988-08-05 | 1992-09-29 | Heathdyne, Inc. | Apparatus and method for kidney dialysis using plasma in lieu of blood |
US5679320A (en) * | 1988-12-29 | 1997-10-21 | Bio-Technology General Corp. | Fibrin binding domain polypeptides and uses and methods of producing same |
CA1335361C (en) * | 1989-05-24 | 1995-04-25 | Andrei Z. Budzynski | Thrombus-targeted complexes of plasminogen activator and fibrin fragments |
US5180615A (en) * | 1989-12-13 | 1993-01-19 | W.R. Grace & Co.-Conn. | Metallized bag for static protection of electronic components |
US5591431A (en) * | 1990-03-09 | 1997-01-07 | G.D. Searle & Co. | Enhancement of clot lysis |
US5753624A (en) * | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
SE502414C2 (sv) * | 1990-05-28 | 1995-10-16 | Ljungqvist Olle Medical Ab | Användning av glukos för framställning av lösning för preoperativ administrering samt infusionslösning därför |
DE69109676T2 (de) * | 1990-06-04 | 1996-02-08 | Health Now | Verminderung von kardiovaskulären gefässverschlüssen mit ascorbat und hemmstoffen der bindung von lipoprotein (a). |
US5650418A (en) | 1990-06-04 | 1997-07-22 | Therapy 2000 | Therapeutic lysine salt composition and method of use |
US5278189A (en) | 1990-06-04 | 1994-01-11 | Rath Matthias W | Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A) |
US5230996A (en) | 1990-06-04 | 1993-07-27 | Therapy 2000 | Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation |
US5780587A (en) | 1990-08-24 | 1998-07-14 | President And Fellows Of Harvard College | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
SE468881B (sv) * | 1991-01-09 | 1993-04-05 | Kabi Pharmacia Ab | Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar |
US5221628A (en) * | 1991-03-19 | 1993-06-22 | Northwestern University | Binding of aggregated immunoglobulin or immune complexes by serum amyloid P component |
US5276059A (en) | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
CA2101614A1 (en) * | 1992-07-30 | 1994-01-31 | Shmuel Shaltiel | Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them |
US5958883A (en) * | 1992-09-23 | 1999-09-28 | Board Of Regents Of The University Of Washington Office Of Technology | Animal models of human amyloidoses |
DE4242736A1 (de) * | 1992-12-17 | 1994-06-23 | Behringwerke Ag | Synthetische Peptide, Antikörper dagegen und ihre Verwendung |
US5955343A (en) * | 1992-12-28 | 1999-09-21 | Massachusetts Institute Of Technology | Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
EP1308461A3 (de) * | 1993-01-25 | 2004-02-11 | Takeda Chemical Industries, Ltd. | Antikörper gegen Beta-Amyloiden oder deren Abarten, und deren Verwendungen |
US5449663A (en) * | 1993-06-11 | 1995-09-12 | Bicher; Haim I. | Antineoplastic compositions |
JP3680114B2 (ja) * | 1993-09-17 | 2005-08-10 | 敏一 中村 | 脳神経障害治療剤 |
ATE249234T1 (de) * | 1993-12-17 | 2003-09-15 | Mochida Pharm Co Ltd | Lösliches thrombomodulin enthaltende zubereitung |
AU692237B2 (en) | 1994-02-03 | 1998-06-04 | Picower Institute For Medical Research, The | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
US6410598B1 (en) * | 1994-02-03 | 2002-06-25 | Michael P. Vitek | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
KR0163563B1 (ko) * | 1994-03-23 | 1998-12-01 | 김종인 | 피부질환 치료용 의약조성물 |
US5786324A (en) * | 1994-03-24 | 1998-07-28 | Regents Of The University Of Minnesota | Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US6136548A (en) * | 1994-11-22 | 2000-10-24 | Rutgers, The State University Of New Jersey | Methods for identifying useful T-PA mutant derivatives for treatment of vascular hemorrhaging |
US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
US5888774A (en) * | 1994-12-19 | 1999-03-30 | Cangene Corporation | Recombinant DNA molecules and expression vectors for erythropoietin |
US5817626A (en) | 1995-03-14 | 1998-10-06 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation |
US5854215A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals Incorporated | Modulators of β-amyloid peptide aggregation |
CA2214247C (en) * | 1995-03-14 | 2004-02-10 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
US5948763A (en) * | 1995-06-07 | 1999-09-07 | New York University | Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits |
US6436969B1 (en) | 1995-09-12 | 2002-08-20 | Kansas University Medical Center Research Institute Inc. | Dialysis solutions and methods |
CA2233059A1 (en) * | 1995-10-02 | 1997-04-10 | Mohammad W. Katoot | Biologically-active polymers |
US5985242A (en) | 1995-10-27 | 1999-11-16 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
US6310046B1 (en) * | 1995-11-17 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Sequestrin of Plasmodium falciparum |
US6001331A (en) * | 1996-01-24 | 1999-12-14 | Warner-Lambert Company | Method of imaging amyloid deposits |
US5785187A (en) * | 1996-04-29 | 1998-07-28 | Lipman; Daniel | Mechandising display assembly |
US6034211A (en) | 1996-06-03 | 2000-03-07 | Kelly; Jeffery W. | β-sheet nucleating peptidomimetics |
US6929807B1 (en) * | 1996-08-09 | 2005-08-16 | Mannatech, Inc. | Compositions of plant carbohydrates as dietary supplements |
IL128335A0 (en) * | 1996-08-09 | 2000-01-31 | Mannatech Inc | Compositions of plant carbohydrates as dietary supplements |
US6689275B1 (en) * | 1996-12-31 | 2004-02-10 | Ajay Gupta | Method and pharmaceutical composition for replacing iron losses in dialysis patients |
US6372473B1 (en) * | 1997-05-28 | 2002-04-16 | Human Genome Sciences, Inc. | Tissue plasminogen activator-like protease |
AU7927398A (en) * | 1997-07-08 | 1999-02-08 | Viventia Biotech Inc. | Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
US20020122807A1 (en) | 1998-07-07 | 2002-09-05 | Dan Michael D. | Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
DE19735902A1 (de) * | 1997-08-19 | 1999-02-25 | Imtec Immundiagnostika Gmbh | Selektives Adsorbens für biologische Materialien |
ES2200366T3 (es) | 1997-08-28 | 2004-03-01 | University Of Washington | Composiciones de sacaridos para el tratamiento de la enfermedad de alzheimer y otras amiloidoisis. |
AU760140B2 (en) | 1997-10-24 | 2003-05-08 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
AU2905699A (en) * | 1998-03-18 | 1999-10-11 | Tyndale Plains-Hunter Ltd. | Hydrophilic polyether polyurethanes containing carboxylic acid |
JP4037525B2 (ja) | 1998-03-25 | 2008-01-23 | 生化学工業株式会社 | 新規抗菌性ペプチド |
US7041287B2 (en) * | 1998-05-21 | 2006-05-09 | Trustees Of The University Of Pennsylvania | Compositions and methods for selective dissolution of nascent intravascular blood clots |
WO2000009562A1 (en) | 1998-08-12 | 2000-02-24 | The New York Blood Center, Inc. | Novel cleaved fragments of fibrinogen |
JP2002525323A (ja) * | 1998-09-25 | 2002-08-13 | スノル・モレキュラー・コーポレーション | 医薬活性化合物及びその使用方法 |
IN190822B (de) * | 1998-12-24 | 2003-08-23 | Council Scient Ind Res | |
US6242473B1 (en) * | 1999-01-08 | 2001-06-05 | Maxim Pharmaceuticals, Inc. | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
US6161547A (en) * | 1999-01-15 | 2000-12-19 | Coaxia, Inc. | Medical device for flow augmentation in patients with occlusive cerebrovascular disease and methods of use |
WO2000059493A2 (en) * | 1999-04-06 | 2000-10-12 | Kansas University Medical Center | Improved dialysis solutions and methods |
ATE319819T1 (de) * | 1999-04-30 | 2006-03-15 | Akira Matsumoto | Humane hirn-spezifische carboxypeptidase b |
ATE384077T1 (de) * | 1999-05-05 | 2008-02-15 | Neurochem Int Ltd | Stereoselektive antifibrillogene peptide |
AT500670A1 (de) * | 1999-05-19 | 2006-02-15 | Bio & Bio Licensing Sa | Arzneimittel zur lokalen anwendung |
ATE405636T1 (de) * | 1999-06-16 | 2008-09-15 | Boston Biomedical Res Inst | Immunologische kontrolle des beta-amyloid gehaltes in vivo |
GB9917725D0 (en) * | 1999-07-28 | 1999-09-29 | Medical Res Council | Peptides |
JP2003507013A (ja) * | 1999-08-13 | 2003-02-25 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | βシートフィブリルのRAGEへの結合を阻害する方法及びその結果 |
US20020052311A1 (en) * | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
US20040013647A1 (en) * | 1999-09-03 | 2004-01-22 | Ramot At Tel-Aviv University Ltd. | Methods and compositions for treating a plaque-forming disease |
ES2202171T3 (es) * | 1999-09-14 | 2004-04-01 | Meiji Seika Kaisha, Ltd. | Derivados del acido fosfonico que poseen actividad inhibidora de la carboxipeptidas b. |
US6399314B1 (en) * | 1999-12-29 | 2002-06-04 | American Cyanamid Company | Methods of detection of amyloidogenic proteins |
AU2001231016A1 (en) | 2000-01-20 | 2001-07-31 | Regents Of The University Of Minnesota | Peptides with antibacterial activity |
WO2001058476A2 (en) * | 2000-02-11 | 2001-08-16 | The European Molecular Biology Laboratory | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity |
EP1259251B1 (de) | 2000-02-21 | 2005-10-19 | Pharmexa A/S | Verfahren zur herabregulierung von amyloid |
MXPA02007796A (es) * | 2000-02-21 | 2003-12-08 | Pharmexa As | Metodo novedoso para la disminucion de cuerpos amiloides. |
EP1130031A1 (de) | 2000-02-25 | 2001-09-05 | Universitair Medisch Centrum Utrecht | Verfahren zur Hemmung der Angiogenese unter Verwendung von Molekülen die die Plasminbildung steigern oder die Plasminaktivität verlängern |
US6686144B2 (en) * | 2000-03-21 | 2004-02-03 | The Research Foundation Of The State University Of New York | Adsorption of polyampholytes to charged surfaces and assays incorporating same |
DE10017690A1 (de) * | 2000-04-08 | 2001-10-25 | Simmoteit Robert | Vorrichtung zum Stoffaustausch und Kultivierung von Zellen |
US7270800B2 (en) | 2000-08-24 | 2007-09-18 | University Of Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
PT2264018E (pt) * | 2000-08-24 | 2015-06-03 | Univ Pittsburgh | Derivados de tioflavina para uso no diagnóstico da doença de alzheimer |
EP1186299A1 (de) * | 2000-09-12 | 2002-03-13 | Universitair Medisch Centrum Utrecht | Diagnose, Verbeugung und/oder Behandlung von Atherosklerose, Infectionen und Störungen des Immunsystems |
US7029655B2 (en) * | 2000-10-04 | 2006-04-18 | California Institute Of Technology | Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits |
DE60032250T2 (de) * | 2000-12-28 | 2007-03-15 | Biomay Produktions- Und Handels-Aktiengesellschaft | Behandlung von Allergien |
WO2002099098A1 (en) * | 2001-04-04 | 2002-12-12 | American Diagnostica, Inc | Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof |
US7166471B2 (en) | 2001-05-31 | 2007-01-23 | Arete Associates | Misfolded protein sensor method in body fluids |
US6960465B1 (en) * | 2001-06-27 | 2005-11-01 | Northwestern University | Increased cell resistance to toxic organic substances |
US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
CA2453403C (en) * | 2001-07-09 | 2013-10-08 | Elan Pharmaceuticals, Inc. | Methods of inhibiting amyloid toxicity |
JP2003024080A (ja) * | 2001-07-19 | 2003-01-28 | Univ Tokyo | p53依存性アポトーシス誘導タンパク質、およびアポトーシス調節剤のスクリーニング方法 |
GB0202275D0 (en) | 2002-01-31 | 2002-03-20 | Hansa Medica Ab | Peptide |
EP1820806A1 (de) * | 2006-02-16 | 2007-08-22 | Crossbeta Biosciences B.V. | Affinitätsbereiche |
ES2564293T5 (es) | 2002-02-28 | 2019-04-04 | Microsens Biophage Ltd | Enlazamiento de formas patológicas de proteínas priónicas |
AU2003230321B8 (en) * | 2002-05-09 | 2009-07-30 | Medigenes | A pharmaceutical composition for treatment of wounds containing blood plasma or serum |
US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
EP1380290A1 (de) | 2002-07-09 | 2004-01-14 | Universitair Medisch Centrum Utrecht | Cross-Beta-Strukturweg und seine therapeutische Relevanz |
US20050142611A1 (en) * | 2002-09-30 | 2005-06-30 | Auburn University | Method of isolation and self-assembly of small protein particles from blood and other biological materials |
US7470667B2 (en) * | 2002-12-05 | 2008-12-30 | Medgenn (Hong Kong) Ltd | Methods of treating cancer using a modified endostatin protein |
EP1449536A1 (de) | 2003-02-14 | 2004-08-25 | Prionics AG | Prioproteine als therapeutische mittel zur behandlung von AP-1 assoziierten krankheiten |
WO2004073651A2 (en) * | 2003-02-18 | 2004-09-02 | The Ohio State University Research Foundation | Identifying inhibitors of intracellular protein fibrillization |
EP2520654B8 (de) | 2003-08-26 | 2017-04-19 | The Regents of the University of Colorado, a body corporate | Serinprotease-Hemmer und deren Verwendung in Verfahren und Zusammensetzungen für die Behandlung bakterieller Infektionen |
ATE462716T1 (de) | 2003-10-24 | 2010-04-15 | Amgen Inc | Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen |
WO2006006172A2 (en) | 2004-07-15 | 2006-01-19 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
US20080299212A1 (en) * | 2005-02-25 | 2008-12-04 | Medigenes Co., Ltd | Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum |
EP1704867A1 (de) | 2005-03-18 | 2006-09-27 | Crossbeta Biosciences B.V. | Cross-Beta Strukturen auf Mikrobenorganismen |
US20090202980A1 (en) * | 2005-03-21 | 2009-08-13 | Crossbeta Biosciences B.V. | Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation |
EP1906995A2 (de) | 2005-07-13 | 2008-04-09 | Crossbeta Biosciences B.V. | Adjuvation durch kreuzstruktur |
US20070015133A1 (en) * | 2005-07-13 | 2007-01-18 | Umc Utrecht Holding B.V. | Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein |
ATE554394T1 (de) * | 2005-07-13 | 2012-05-15 | Crossbeta Biosciences Bv | Cross-beta-struktur-bindende verbindungen |
US8114832B2 (en) | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
US20080249606A1 (en) * | 2005-07-13 | 2008-10-09 | Martijn Frans Ben Gerard Gebbink | Methods for Determining the Effect of a Treatment on the Cross-Beta Structure Content of a Protein; Selection of Treatments and Uses Thereof |
WO2007018400A1 (en) | 2005-08-11 | 2007-02-15 | Medigenes Co., Ltd | Pharmaceutical composition for the treatment of nerve damage comprising blood plasma or serum |
US8543424B2 (en) * | 2005-12-30 | 2013-09-24 | Darryl Mark Hunsaker | Vehicle insurance status display system |
WO2007108675A1 (en) | 2006-03-17 | 2007-09-27 | Crossbeta Biosciences B.V. | Methods of binding of cross-beta structures by chaperones |
ES2599319T3 (es) | 2006-06-26 | 2017-02-01 | Macrogenics, Inc. | Anticuerpos específicos de Fc RIIB y métodos de uso de éstos |
EP2058000A1 (de) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung |
EP2058001A1 (de) * | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Steigerung der Immunogenizität von Antigenen |
-
2002
- 2002-07-09 EP EP02077797A patent/EP1380290A1/de not_active Withdrawn
-
2003
- 2003-07-08 PT PT03762927T patent/PT1536778E/pt unknown
- 2003-07-08 DK DK03762927T patent/DK1536778T3/da active
- 2003-07-08 AU AU2003251233A patent/AU2003251233B2/en not_active Ceased
- 2003-07-08 WO PCT/NL2003/000501 patent/WO2004004698A2/en active Application Filing
- 2003-07-08 JP JP2004519368A patent/JP2005537254A/ja active Pending
- 2003-07-08 EP EP11153594A patent/EP2341348A1/de not_active Withdrawn
- 2003-07-08 EP EP03762927A patent/EP1536778B1/de not_active Expired - Lifetime
- 2003-07-08 NZ NZ537495A patent/NZ537495A/en not_active IP Right Cessation
- 2003-07-08 NZ NZ561168A patent/NZ561168A/en not_active IP Right Cessation
- 2003-07-08 AT AT03762927T patent/ATE417605T1/de active
- 2003-07-08 DE DE60325381T patent/DE60325381D1/de not_active Expired - Lifetime
- 2003-07-08 ES ES03762927T patent/ES2319982T3/es not_active Expired - Lifetime
- 2003-07-08 EP EP08153132A patent/EP1978362A3/de not_active Withdrawn
- 2003-07-08 EP EP10185187A patent/EP2322154A3/de not_active Withdrawn
- 2003-07-08 CA CA002492010A patent/CA2492010A1/en not_active Abandoned
-
2005
- 2005-01-04 ZA ZA200500062A patent/ZA200500062B/en unknown
- 2005-01-10 US US11/033,105 patent/US20060045853A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/982,161 patent/US8158585B2/en not_active Expired - Fee Related
-
2010
- 2010-01-29 AU AU2010200343A patent/AU2010200343A1/en not_active Abandoned
-
2012
- 2012-04-02 US US13/437,807 patent/US20120189615A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20060045853A1 (en) | 2006-03-02 |
EP1978362A2 (de) | 2008-10-08 |
EP1380290A1 (de) | 2004-01-14 |
WO2004004698A2 (en) | 2004-01-15 |
EP1536778B1 (de) | 2008-12-17 |
EP1978362A3 (de) | 2009-02-11 |
US8158585B2 (en) | 2012-04-17 |
ZA200500062B (en) | 2005-11-01 |
AU2003251233A1 (en) | 2004-01-23 |
WO2004004698A3 (en) | 2004-06-10 |
US20120189615A1 (en) | 2012-07-26 |
EP2322154A3 (de) | 2011-10-05 |
EP1536778A2 (de) | 2005-06-08 |
US20080241165A1 (en) | 2008-10-02 |
PT1536778E (pt) | 2009-03-24 |
ES2319982T3 (es) | 2009-05-18 |
DK1536778T3 (da) | 2009-04-14 |
AU2010200343A1 (en) | 2010-02-18 |
EP2341348A1 (de) | 2011-07-06 |
NZ561168A (en) | 2009-06-26 |
DE60325381D1 (de) | 2009-01-29 |
CA2492010A1 (en) | 2004-01-15 |
JP2005537254A (ja) | 2005-12-08 |
EP2322154A2 (de) | 2011-05-18 |
AU2003251233B2 (en) | 2009-10-29 |
NZ537495A (en) | 2009-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE417605T1 (de) | Proteine die cross-beta-struktur enthaltendes amyloid binden, sowie verfahren zur modulation der cross-beta-struktur, ihrer bildung und der damit zusammenhängenden toxizität | |
WO2006101387A3 (en) | Method for interfering with blood coagulation by modulating cross-beta structures fibril formation | |
DE60143192D1 (de) | Zellen zur entdeckung von medikamenten | |
ATE535529T1 (de) | Verfahren zur acylierung von maytansinol mit chiralen aminosäuren | |
BRPI0513029A (pt) | método para produzir uma proteìna de eritropoietina carbamilada, proteìna de eritropoietina carbamilada, composto, composição farmacêutica, métodos de tratamento de uma doença ou condição crÈnica, sub-crÈnica e aguda e de tratamento de uma doença do sistema nervoso central ou sistema nervoso periférico, e, uso de um composto | |
DE602005023877D1 (de) | Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide | |
WO2005017205A3 (en) | Nucleic acid mapping using linear analysis | |
DE69839444D1 (de) | Smad 6 und dessen anwendungen | |
ATE368688T1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
ATE463294T1 (de) | Verfahren zur konzentration und reinigung von biologischen verbindungen | |
WO2004029072A3 (en) | PrPsc -INTERACTING MOLECULES AND USES THEREOF | |
DE60138715D1 (de) | Tnf-rezeptor-ähnliche moleküle und deren anwendungen | |
ATE449104T1 (de) | Verfahren zur reinigung von fibrinogen | |
DE10390418D2 (de) | Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen | |
ATE439441T1 (de) | Veränderte, fluoreszierende proteine | |
DE60307830D1 (de) | Neue multimerische moleküle, verfahren zu deren herstellung, und deren verwendung zur herstellung von arzneimitteln | |
ATE405834T1 (de) | Bindungsoberfläche | |
ATE291621T1 (de) | Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen | |
DK1051491T3 (da) | Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf | |
WO2001064837A8 (en) | β NETRIN AND USES THEREOF | |
DK1622929T3 (da) | Apo-2L (TRAIL) receptorbindingspeptider og anvendelser deraf | |
DE60124376D1 (de) | Funktionalisierter festträger zur organischen synthese von peptiden und kleinen molekülen | |
ATE550345T1 (de) | Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren | |
DE602005012173D1 (de) | Verfahren zur Herstellung von extrachromosomalen Nukleinsäuremolekülen | |
ATE384117T1 (de) | Verwendung einer miniaturvorrichtung zur trennung und isolierung biologischer objekte und trennungsverfahren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1536778 Country of ref document: EP |